Explore Our Library of Biomanufacturing Resources & Technical Data

Application Notes

A Binding Advantage: Optibumin 25 Demonstrates Enhanced Drug Binding and Consistency over Plasma Albumin

Enhanced Cryopreservation of T Cells Using Optibumin®, Recombinant Human Serum Albumin (rHSA)

High-Resolution Analytical Characterization of Optibumin®: Structural Homogeneity and Functional Consistency Compared to Plasma-Derived HSA

Improved iPSC Cryopreservation with Optibumin 25: Enhanced Viability, Expansion, and Pluripotency

Low-DMSO Cryopreservation of MSCs with Optibumin 25 Recombinant Albumin

Maintaining Viable Cell Count in Primary T Cells During Cell Washing Using Optibumin®

Preserving Lentiviral Titer During Sterile Filtration Using Recombinant Albumin

Recombinant Albumin as a Carrier Protein Improves Cytokine Recovery and Functional Stability at Dilute Concentrations

Retain and Protect Final Cell Product with Optibumin®, a Recombinant Human Serum Albumin (rHSA)

Superior Cryopreservation of T Cells in Low-DMSO, Animal-Origin-Free Formulation Using Optibumin 25 and PentaHibe Base

Sustained T Cell Proliferation and Early Memory Retention with OptiLeukin™ 2 Recombinant IL-2

Thiol by Combat: Enhanced Covalent Conjugation with Recombinant Albumin Compared to Human Plasma-Derived Albumin

Blog

Albumin in Drug Delivery: Cancer’s Unexpected Achilles’ Heel

Consistency Is the New Compliance

Cryopreservation Just Got Better with Optibumin® 25

Evolving Challenges in Closed-System Biomanufacturing

How Regulatory Bodies Are Driving the Shift to Animal-Origin-Free Solutions in Cell Therapy and Vaccine Development

Innovative Solutions in Closed-System Biomanufacturing: Exploring the Tools and Technologies Driving Sterility and Efficiency

Optibumin vs Traditional Albumin: Comparing Performance in Cell Wash Applications

Scaling Innovation: How DiscGenics and InVitria are Leading the Future of Cell Therapy

Why Border Disruptions Threaten Blood-Derived Raw Materials—and What Biomanufacturers Can Do About It

Why Do Some Biologics Cross the Finish Line—While Others Crash and Burn?

Case Studies

How Merck Used Recombinant Albumin in ERVEBO to Establish a Novel Excipient Pathway

Catalog

InVitria Product Catalog

Data Sheets

Optibumin 25 – Data Sheet

Infographics

Optimizing CAR-T Manufacturing with Defined, AOF Components

News

InVitria Launches Optibumin 25 rHSA

InVitria Presents ASGCT 2026 Data on rHSA for Lentiviral Vector Manufacturing

InVitria Showcases Exbumin and Optibumin 25 at IPEC Excipient World: Biologics Summit

Posters

Better Cells, Better Outcomes: Improving CAR-T Manufacturing with Animal-Free Cryopreservation and Wash Solutions

Enhanced Cryopreservation of Therapeutically Relevant Cells

Enhancing Cell Therapy Consistency and Safety

Recombinant Albumin Preserves Dilute Cytokine Recovery and Bioactivity at Room Temperature

Stronger Cells for Safer Therapies: Low-DMSO, Animal-Origin-Free T Cell Cryopreservation with Optibumin 25 and PentaHibe

Regulatory Documents

Certificate of Origin and Animal-Free / TSE-BSE Statement

cGMP Statement

ISO 9001:2015 Certificate of Registration

SDS

Optibumin 25 – Safety Data Sheet

Use Guidelines

Optibumin 25 – Guidelines for Use

Webinar

Why Cell Quality Erodes During Downstream Processing — and How to Prevent It | Webinar

White Papers

Emergence of Blood-Free Recombinant Human Albumin

Optimizing the Performance of LNP and Liposome Therapeutics with Blood-Free Recombinant Albumin